SCHOLAR ROCK HOLDING CORPORATION Lease Obligation Incurred
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Lease Obligation Incurred of $44.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-19.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2019-03-19
- SCHOLAR ROCK HOLDING CORPORATION lease obligation incurred for the quarter ending 2018-12-31 was $0.00.
- SCHOLAR ROCK HOLDING CORPORATION lease obligation incurred for fiscal 2018 was $44.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $44.00K 10-K · filed 2019-03-19 | |
| 2018-09-30 | $44.00K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |